Federated Hermes, Inc. Viking Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$5.19 - $6.73 $2,428 - $3,149	-468 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$5.74 - $9.67 $269 - $454	-47 Reduced 9.13%	468 $3,000
Q4 2020 Feb 12, 2021	BUY	$5.3 - $6.71 $890 - $1,127	168 Added 48.41%	515 $3,000
Q3 2020 Nov 12, 2020	BUY	$5.73 - $8.11 $1,008 - $1,427	176 Added 102.92%	347 $2,000
Q2 2020 Aug 13, 2020	SELL	$4.35 - $8.08 $1.08 Million - $2.01 Million	-248,966 Reduced 99.93%	171 $1,000
Q1 2020 May 13, 2020	BUY	$3.45 - $7.95 $377,278 - $869,380	109,356 Added 78.23%	249,137 $1.17 Million
Q4 2019 Feb 14, 2020	BUY	$6.38 - $8.73 $692,357 - $947,379	108,520 Added 347.14%	139,781 $1.12 Million
Q3 2019 Nov 14, 2019	BUY	$6.55 - $8.6 $204,759 - $268,844	31,261 New	31,261 $215,000

474

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.18B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.